S. Kunitada

发表

Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction.

G. FitzGerald, D. Fitzgerald, S. Kunitada, 1992, Blood.

First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary Disease: A Pharmacokinetic and Pharmacodynamic Evaluation

V. Hasselblad, P. Armstrong, R. Becker, 2002, Circulation.

Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux

M. Wolzt, S. Kapiotis, K. Ogata, 2011, Thrombosis and Haemostasis.

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

S. Connolly, J. Weitz, H. Kastrissios, 2010, Thrombosis and Haemostasis.

Tolerability, pharmacokinetics, and pharmacodynamics of DX‐9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers

Y. Terada, Y. Ikeda, S. Kunitada, 1999, Clinical pharmacology and therapeutics.

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

E. Antman, R. Giugliano, S. Zhou, 2012, Thrombosis and Haemostasis.

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

J. Mendell, S. Kunitada, Masaya Tachibana, 2011, Journal of clinical pharmacology.

Vascular Endothelial Tissue Factor Pathway Inhibitor Kinetics in Culture Following Exposure to DX-9065a—A Selective and Direct Factor Xa Inhibitor

R. Becker, J. Alexander, R. Harrington, 2004, Journal of Thrombosis and Thrombolysis.

Initial experience with factor‐Xa inhibition in percutaneous coronary intervention: the XaNADU‐PCI Pilot

V. Hasselblad, R. Becker, J. Alexander, 2004, Journal of thrombosis and haemostasis : JTH.

Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - A direct and selective antagonist

R. Becker, J. Alexander, R. Harrington, 2004, Thrombosis and Haemostasis.

Antithrombotic Effects of DX-9065a, a Direct Factor Xa Inhibitor

V. Fuster, J. Badimón, D. Shimbo, 2002, Thrombosis and Haemostasis.

Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber

V. Fuster, J. Badimón, P. Moreno, 2007, Thrombosis and Haemostasis.

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

H. Masumoto, K. Ogata, S. Kunitada, 2010, Journal of clinical pharmacology.

In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.

M. Samama, J. Mendell, L. Le Flem, 2012, Thrombosis research.

Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.

F. Depasse, M. Samama, S. Heptinstall, 2010, Thrombosis research.

FXa inhibitors : Updates on clinical trial

S. Kunitada, Y. Shimoto, 2009 .

Antithrombotic and Hemorrhagic Effects of DX-9065a, a Direct and Selective Factor Xa Inhibitor: Comparison with a Direct Thrombin Inhibitor and Antithrombin Ill-Dependent Anticoagulants

Y. Terada, S. Kunitada, Y. Morishima, 1997, Thrombosis and Haemostasis.

A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats.

B. Kaiser, S. Kunitada, J. Fareed, 2000, Thrombosis research.

Pharmacokinetics of Tissue‐Type Plasminogen Activator During Acute Myocardial Infarction in Men: Effect of a Prostacyclin Analogue

G. FitzGerald, D. Fitzgerald, D. Kerins, 1992, Circulation.

Clinical safety, tolerability, pharmacokinetics and pharmacodynamics of the novel factor Xa inhibitor DY-807f in healthy volunteers.

Takako Shimizu, H. Masumoto, K. Ogata, 2015, Thrombosis research.

A thromboxane A2 synthase inhibitor, DP-1904, prevents rat renal injury.

S. Ashida, S. Kunitada, Y. Abe, 1991, European journal of pharmacology.

A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy.

S. Ashida, S. Kunitada, Y. Abe, 1992, European journal of pharmacology.

Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.

S. Kunitada, Y. Morishima, T. Hara, 1995, Thrombosis research.

A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats.

T. Kondo, S. Kunitada, T. Shibutani, 1999, Thrombosis research.

Molecular model of an interaction between factor Xa and DX-9065a, a novel factor Xa inhibitor: Contribution of the acetimidoylpyrrolidine moiety of the inhibitor to potency and selectivity for serine proteases

S. Kunitada, S. Katakura, M. Iwamoto, 1995 .

Increases in plasma cyclic AMP dependent on endogenous catecholamines.

M. Ui, M. Honma, S. Kunitada, 1978, European journal of pharmacology.

Xo lnhibitor : Comporison with o Direcl Thrombin lnhibitor ond Antithrombin lll-Dependent Anticoogulonls

Y. Terada, S. Kunitada, Y. Morishima, 2018 .

DX-9065a, an Orally Active Factor Xa Inhibitor, Does not Facilitate Haemorrhage Induced by Tail Transection or Gastric Ulcer at the Effective Doses in Rat Thrombosis Model

Y. Terada, S. Kunitada, Y. Morishima, 1999, Thrombosis and Haemostasis.

DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITIES OF ORALLY ACTIVE COAGULATION FACTOR Xa INHIBITORS

S. Kunitada, H. Ishihara, Y. Morishima, 1995, European Journal of Medicinal Chemistry.

Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates.

S. Hanson, L. Harker, U. Marzec, 1995, Circulation.

Factor Xa-Inhibitor (Dx-9065a) Modulates the Leukocyte-Endothelial Cell Interaction in Endotoxemic Rat

T. Iba, A. Kidokoro, S. Kunitada, 2002, Shock.

The plasma cyclic AMP response to catecholamines as potentiated by phentolamine in rats.

M. Ui, S. Kunitada, 1978, European journal of pharmacology.

Functional and metabolic effects of bucladesine (dibutyryl cyclic AMP) in the working rat heart preparation: comparison with dopamine.

S. Kunitada, K. Tamura, H. Hashimoto, 1989, Archives internationales de pharmacodynamie et de therapie.

Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation

S. Connolly, J. Weitz, S. Kunitada, 2008 .

Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule

I. Wilding, A. Connor, K. Ogata, 2015, Journal of clinical pharmacology.

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

H. Masumoto, K. Ogata, S. Kunitada, 2010, Journal of clinical pharmacology.